Davies Janine M, Goldberg Richard M
Division of Hematology and Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27590, USA.
Oncology (Williston Park). 2008 Nov 30;22(13):1470-9.
The treatment of metastatic colorectal cancer (mCRC) has changed dramatically from the 1980s, when only fluorouracil (5-FU) was available for treatment and the median survival was at best 12 months, to a time when mCRC is considered more of a chronic disease in which the median survival is now reported in excess of 2 years. This review traces the evolution of treatment in this setting, including studies of single-agent vs combination treatment with 5-FU/leucovorin, irinotecan, oxaliplatin, and capecitabine, comparisons of simultaneous and sequential regimens, and the role of targeted agents such as bevacizumab, cetuximab, and panitumumab.
转移性结直肠癌（mCRC）的治疗自20世纪80年代以来发生了巨大变化。当时，只有氟尿嘧啶（5-FU）可用于治疗，中位生存期最长为12个月。到了现在，mCRC更多地被视为一种慢性病，目前报道的中位生存期超过2年。本综述追溯了这种情况下治疗方法的演变，包括单药治疗与5-氟尿嘧啶/亚叶酸、伊立替康、奥沙利铂和卡培他滨联合治疗的研究、同步和序贯方案的比较，以及贝伐单抗、西妥昔单抗和帕尼单抗等靶向药物的作用。
